热门资讯> 正文

Iambic Therapeutics任命Michael Secora为首席企业发展官兼首席财务官

2025-01-06 21:14

RECURSION PHARMACEUTICALS(RXRX) 0

Iambic Therapeutics has announced that Michael Secora, Ph.D. will be its Chief Corporate Development Officer and CFO.
Dr Secora will lead Iambic's finance and corporate development activities, helping frame its growing pipeline and industry-leading platform to potential partners, investors, and other stakeholders.
At Recursion (RXRX), he led finance, communications, and investor relations activities as well as corporate strategy for translating value both internally and externally across Recursion's internal pipeline, external partnerships, and data.

More on Recursion Pharmaceuticals

Recursion: Transforming Drug Discovery With Its AI-Powered Drug Development Platform
Recursion: Undruggable CDK12 Protein Target Might Be Possible With REC-1245
Recursion: No News Isn't Good News When It Comes To Vanilla Pipeline
Recursion, Exscientia seek support for merger ahead of special meeting
Why Recursion is getting love as an AI and drug discovery top pick

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。